-
Takeda resubmits new drug applications for Type 2 diabetes treatments
OSAKA, Japan — Japanese drug maker Takeda Pharmaceutical is reapplying for approval of two drugs to treat Type 2 diabetes after the Food and Drug Administration turned down its last applications, the company said.
Takeda announced that it resubmitted its applications for alogliptin and a drug that combines alogliptin with pioglitazone, the active ingredient in Actos, which the FDA approved in 1999.
The FDA will review the applications over the next six months, the drug maker said.
-
Clif Crunch, Clif Mojo expand lines with new flavors
EMERYVILLE, Calif. — Clif Crunch and Clif Mojo on Tuesday announced the expansion of their snack bar lineups with new flavors that now are available at grocery, natural food and mass merchandise stores nationwide.
Clif Crunch, the crunchy granola bar made with organic ingredients, has introduced blueberry crisp and chocolate peanut butter. The new Clif Crunch flavors will sell for a suggested retail price of $3.99 per 10-bar box.